1
Return

Early clinical recovery in STEMI cardiogenic shock: insights from the DanGer shock trial

delete2026-03-01
delete1
PRE
AI
R
Rasmus Paulin Beske
A
Anika Klein
J
Jensen, Lisette Okkels
E
Eiskjaer, Hans
N
Norman Mangner
P
Polzin, Amin
S
Schulze, P. Christian
C
Carsten Skurk
P
Peter Nordbeck
K
Kupriyanova, Yuliya
P
Panoulas, Vasileios
S
Sebastian Zimmer
A
Andreas Schäfer
C
Christian Hassager
M
Moller, Jacob Eifer *
DOI:10.1093/ehjacc/zuag029delete
deleteOriginal
deleteOriginal request for help
deleteShare
deleteSave
Abstract

Abstract

En 中文
Aims The DanGer Shock trial demonstrated a mortality benefit with routine use of a microaxial flow pump (mAFP) in ST-elevation acute myocardial infarction complicated by cardiogenic shock (STEMI-CS), but at a cost of more complications. Routine use of a mAFP may, however, expose some patients to unnecessary risk, underscoring the need to identify those who stabilize rapidly and are less likely to derive benefit from device therapy. Methods and results This post hoc exploratory analysis of the DanGer Shock trial, which randomized STEMI-CS patients to mAFP plus standard care (SoC) or SoC alone, defined 'Fast Recovery' as cardiac intensive care unit (CICU) discharge alive within 3 days of randomization. Baseline variables available at catheterization lab admission associated with 'Fast Recovery' in the SoC arm were identified. Among 355 patients (SoC 176; mAFP 179), 'Fast Recovery' occurred in 29% of the SoC group vs. 15% of the mAFP group. Early CICU discharge favoured SoC through day 3 (HR 2.27, 95% CI 1.48-3.49), with no difference thereafter. Median CICU stay beyond day 3 was 13 days (SoC) vs. 12 days (mAFP), and 94 deaths occurred by day 3 (29% SoC; 24% mAFP). Compared with patients with longer CICU stays, 'Fast Recovery' patients required less inotropic support (44% vs. 85%) and mechanical ventilation (35% vs. 82%) and had lower 180-day mortality (9% vs. 46%, P < 0.001). In the SoC arm, 'Fast Recovery' was associated with lower age, initial higher LVEF, lower heart rate, and lower lactate. Model discrimination was modest (AUROC optimism-corrected 0.74). Conclusion The DanGer Shock trial showed a survival benefit of mAFP use in STEMI-CS, yet about one-third of SoC patients experienced rapid haemodynamic recovery. These 'Fast Recovery' patients were characterized by higher LVEF, younger age, and lower lactate, however discrimination between patients with and without rapid recovery was modest. Distinguishing patients who will recover rapidly remains challenging and warrants further investigation.
Keywords:
Cardiogenic Shock
Randomized clinical trial
Mechanical circulatory support
Prognostication
Microaxial flow pump

Journal

European Heart Journal-Acute Cardiovascular Care cover
European Heart Journal-Acute Cardiovascular Care
IF:
4.6
Papers:
1.4K
Citations:
3.2K

Organization

C
charite universitatsmedizin berlin
Scholars:
311
Papers: 210
Citations: 0
F
Friedrich Schiller University of Jena
Scholars:
1.9W
Papers: 1.5W
Citations: 25
R
Rigshospitalet
Scholars:
1.7W
Papers: 1.3W
Citations: 2.1W
A
aarhus university
Scholars:
3.7K
Papers: 1.6K
Citations: 0
H
heinrich heine university dusseldorf hospital
Scholars:
2.5K
Papers: 1.7K
Citations: 3
C
carl gustav carus university hospital
Scholars:
5.3K
Papers: 4.0K
Citations: 1
G
german heart center berlin
Scholars:
1.7K
Papers: 1.3K
Citations: 2
U
university of copenhagen
Scholars:
6.3K
Papers: 2.5K
Citations: 0
U
university of southern denmark
Scholars:
3.1K
Papers: 1.4K
Citations: 1
H
Humboldt University of Berlin
Scholars:
3.2W
Papers: 2.7W
Citations: 47
T
Technische Universitat Dresden
Scholars:
3.2W
Papers: 2.5W
Citations: 249
O
odense university hospital
Scholars:
7.1K
Papers: 6.0K
Citations: 93
Cited Papers

Cited Papers

Citing Papers

Citing Papers